XOMA Royalty Corporation (XOMA)
NASDAQ: XOMA · Real-Time Price · USD
33.35
-1.45 (-4.15%)
At close: Oct 29, 2025, 4:00 PM EDT
33.35
+0.01 (0.01%)
After-hours: Oct 29, 2025, 5:20 PM EDT
XOMA Royalty Employees
XOMA Royalty had 13 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
13
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$3,457,846
Profits / Employee
-$1,255,462
Market Cap
403.06M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 13 | 0 | - |
| Dec 31, 2023 | 13 | 0 | - |
| Dec 31, 2022 | 13 | 1 | 8.33% |
| Dec 31, 2021 | 12 | 2 | 20.00% |
| Dec 31, 2020 | 10 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
XOMA News
- 12 days ago - XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement - GlobeNewsWire
- 26 days ago - XOMA Royalty PFD Update: Going Back To My Original Sell Ratings - Seeking Alpha
- 27 days ago - XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V. - GlobeNewsWire
- 5 weeks ago - ESSA Pharma Inc. Amends Agreement with XenoTherapeutics - PRNewsWire
- 5 weeks ago - XOMA Royalty Declares Quarterly Preferred Stock Dividends - GlobeNewsWire
- 6 weeks ago - XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc. - GlobeNewsWire
- 2 months ago - XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share - GlobeNewsWire